Answers are grounded in this paper and cite their sources.
Reviews vasopressor selection in adult shock states, highlighting that no single agent provides a proven mortality benefit despite norepinephrine remaining the preferred choice.
Vasopressors are a heterogeneous potent class of medications designed to increase blood pressure in emergent hypotensive situations. The goal of therapy is to increase blood pressure and maintain adequate perfusion, allowing nutrient and oxygen delivery to vital organs. Norepinephrine, phenylephrine, dopamine, epinephrine, and vasopressin are five vasopressors available in the United States. All vasopressors, with the exception of vasopressin, are titratable and dosed on a continuum according to clinical effect. With their different clinical features, adverse effects, and range of potency, the clinical situation usually guides therapy. Outcome data comparing different vasopressors have not demonstrated a clear mortality benefit of any one vasopressor over another, and physician preference also guides therapy. Norepinephrine, nonetheless, remains one of the preferred choices for a variety of hypotensive states, including cardiogenic and septic shock.
No takes yet. Share an insight, caveat, or question.
Nadia Ferguson-Myrthil (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: